22 March 2021

Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC

2021-03-22T12:16:54-07:00

*February 2021* In EGFR-mutant non–small cell lung cancer (NSCLC) and brain metastases, oral osimertinib (Tagrisso) achieved rapid, high, and uniform

Osimertinib Penetrates Blood-Brain Barrier and Decreases Metastasis in EGFR+ NSCLC2021-03-22T12:16:54-07:00
22 March 2021

TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer, But May Be Eclipsed by ADCs

2021-03-22T11:14:02-07:00

*January 2021* Poziotinib, mobocertinib (TAK-788), and fam-trastuzumab deruxtecan-nxki (Enhertu) are among some of the agents that have positioned HER2 as a must-test

TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer, But May Be Eclipsed by ADCs2021-03-22T11:14:02-07:00
22 March 2021

Chemoimmunotherapy Continues to Display Survival Benefits in Small Cell Lung Cancer

2021-03-22T10:33:15-07:00

*January 2021* Atezolizumab (Tecentriq), durvalumab (Imfinzi), pembrolizumab (Keytruda), and nivolumab (Opdivo) have demonstrated improved survival in combination with etoposide and

Chemoimmunotherapy Continues to Display Survival Benefits in Small Cell Lung Cancer2021-03-22T10:33:15-07:00
17 March 2021

Osimertinib/Bevacizumab Improves ORR, But Fails to Prolong PFS in EGFR T790M+ NSCLC

2021-03-17T09:13:42-07:00

*January 2021* The combination of osimertinib (Tagrisso) plus bevacizumab (Avastin) failed to result in a statistically significant improvement in progression-free

Osimertinib/Bevacizumab Improves ORR, But Fails to Prolong PFS in EGFR T790M+ NSCLC2021-03-17T09:13:42-07:00
6 March 2021

Multicenter Analysis of Mechanisms of Resistance to Osimertinib in EGFR Mutated NSCLC: An ATOMIC Registry Study

2021-03-06T10:31:16-08:00

*January 2021* The ATOMIC consortium is a group of thoracic oncologists from North America. They received funding from AstraZeneca to

Multicenter Analysis of Mechanisms of Resistance to Osimertinib in EGFR Mutated NSCLC: An ATOMIC Registry Study2021-03-06T10:31:16-08:00
6 March 2021

Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC

2021-03-06T10:19:23-08:00

*January 2021* Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell

Patritumab Deruxtecan Shows Early Activity in Metastatic EGFR-Mutant NSCLC2021-03-06T10:19:23-08:00
Go to Top